Ipilimumab for advanced melanoma: a pharmacologic perspective

Area of Science:

• Immunology
• Oncology
• Pharmacology

Background:

• Ipilimumab, a fully human anti-CTLA-4 antibody, is approved for unresectable or metastatic melanoma.
• Its approval is based on survival benefits shown in phase III clinical trials.

Purpose of the Study:

• To describe the approved dosing schedule and immune-mediated mechanism of action of ipilimumab.
• To introduce revised response criteria for ipilimumab therapy.
• To outline the safety profile and management of immune-related adverse events associated with ipilimumab.

Main Methods:

• Review of randomized phase III studies demonstrating survival benefit.
• Description of the current dosing regimen: 3 mg/kg intravenously every 3 weeks for 4 doses.
• Characterization of immune-related adverse events and management guidelines.

Main Results:

• Ipilimumab demonstrates survival benefit in metastatic melanoma.
• Immune-mediated action leads to distinct tumor response patterns.
• High-grade immune-related adverse events occur in 15% of patients, requiring prompt management.

Conclusions:

• Revised response criteria are under validation to accurately assess ipilimumab efficacy.
• Management of immune-related adverse events is crucial for patient safety.
• Ongoing research aims to optimize ipilimumab use in various settings and combinations.